Correction: Raha et al. Lipid-Lowering Drug Gemfibrozil Protects Mice from Tay-Sachs Disease via Peroxisome Proliferator-Activated Receptor α. Cells 2023, 12, 2791
Sumita Raha, Debashis Dutta, Ramesh K. Paidi, Kalipada Pahan
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMetabolism and Genetic Disorders · Peroxisome Proliferator-Activated Receptors · RNA regulation and disease
Error in Figure 4
In the original publication [1], there was a mistake in Figure 4. One image was incorrectly provided for the Non-Tg (upper left panel) group of Figure 4E that had an overlap with Figure 4C—PAS. This happened due to the simultaneous processing of numerous images, involving contrasting and cropping, while working with multiple open windows on a laptop. It has now been corrected. Please see the corrected Figure 4E below.
Wrong Model
We would also like to report an error in the strain of the animals that was said to have been used in this study. Throughout the study, we used B6;129S4-Hexb^tm1Rlp^/J mice lacking the Hexb gene, which model a severe form of Tay–Sachs (Sandhoff) disease.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
The reference list from the paper itself. Each links out to its DOI / PubMed record.